Inclusion Criteria:

          -  Must have a diagnosis of recurrent epithelial ovarian, primary peritoneal or fallopian
             tube carcinoma with refractory or platinum resistant disease and/or have received ≥ 2
             lines of chemotherapy

          -  Age ≥ 18 years of age

          -  No significant immunodeficiency

          -  Have been informed of other treatment options

          -  Must be HLA A*0201, HLA-A*0205, and/or HLA-A*0206 positive by high resolution testing.

          -  Patient's tumor must be positive by histological assay for NY-ESO-1ᶜ²⁵⁹T, according to
             the screening algorithm as described in Section 3.3.1. Positive expression is defined
             as ≥ 50% of cells that are 2+ and/or 3+ by immunohistochemistry

          -  ECOG performance status of 0 or 1

          -  Life expectancy of > 4 months

          -  Prior therapies:

               1. prior immunotherapy, or prior investigational agents should be washed out 4 weeks
                  before apheresis and must be completed 4 weeks prior to pre-infusion
                  lymphodepletive chemotherapy.

               2. monoclonal antibody therapy must be completed at least 6 weeks prior to
                  pre-infusion lymphodepletive chemotherapy

               3. All previous cytotoxic chemotherapy, monoclonal antibody therapy, immune therapy
                  should be washed out 3 weeks before apheresis and must be completed at least 3
                  weeks prior to pre-infusion lymphodepletive chemotherapy.

               4. Systemic corticosteroid or other immunosuppressive therapy should be washed out 2
                  weeks before apheresis and must be completed at least 2 weeks prior to
                  pre-infusion lymphodepletive chemotherapy

               5. Biologic or other approved molecular targeted small molecule inhibitors should be
                  washed out 1 week before apheresis and must be completed at least 1 week prior to
                  pre-infusion lymphodepletive chemotherapy.

               6. Any grade 3 or 4 -hematologic toxicity of previous therapy must have resolved to
                  grade 2 or less prior to apheresis and any grade 3 or 4 toxicity must have
                  resolved to grade 2 or less prior to pre-infusion lymphodepletive chemotherapy.

          -  Must have measurable disease as defined by RECIST 1.1.

          -  Must have adequate venous access for apheresis.

          -  Women of childbearing potential are requested to use acceptable methods of birth
             control for the duration of the study and until persistence of the study drug is no
             longer detected in the patient. This may be a period of several years. Methods for
             acceptable birth control include: condoms, diaphragm or cervical cap with spermicide,
             intrauterine device, and hormonal contraception. It is recommended that a combination
             of two methods be used.

        Patients must have normal organ and marrow function as defined below:

          -  Leukocytes ≥ 3,000/mcL

          -  Absolute Neutrophil Count ≥ 1,500/mcL

          -  Platelets ≥ 100,000/mcL

          -  Total bilirubin ≤ 1.5 ULN

          -  AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal

          -  creatinine ≤ 2.0 mg/dL OR

          -  creatinine clearance > 60 mL/min for patients with creatinine levels above
             institutional normal

          -  Patient must understand the investigational nature of this study and sign an
             Independent Ethics Committee/Institutional Review Board approved written informed
             consent form prior to receiving any study related procedure.

        Exclusion Criteria:

          -  Currently receiving any other investigational agents

          -  Patients with active brain metastases. Patients with prior history of brain metastasis
             who have undergone local therapy (i.e. metastatectomy and/or radiation) and show no
             evidence of local recurrence or progression over the past 6 months are eligible

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to cyclophosphamide or other agents used in the study

          -  Prior malignancy (except non-melanoma skin cancer) within 18 months of study entry
             NOTE: Patients must be in complete remission from prior malignancy in order to be
             eligible to enter the study.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents (e.g.
             interleukin-2, interferon-alpha or gamma, granulocyte colony stimulating factors,
             etc.) within 30 days prior to study entry. NOTE: Recent or current use of inhaled
             steroids is not exclusionary. If subjects are prescribed a brief course of oral
             corticosteroids, the use should be limited to less than 7 days. Use of steroids before
             apheresis and immune assessment blood draws should be discouraged as it will affect
             white blood cell function.

          -  Active infection with HIV, HBV or HCV

          -  Receipt of an experimental vaccine within 2 months or in the opinion of the
             Investigator is responding to an experimental vaccine given within 6 months, or has
             received any previous gene therapy using an integrating vector

          -  History of severe autoimmune disease requiring steroids or other immunosuppressive
             treatments

          -  Lack of availability of a patient for immunological and clinical follow-up assessment

          -  Evidence or history of significant cardiac disease